Du D L, Volpe D A, Murphy M J
Hipple Cancer Research Center, Dayton, Ohio 45439-2092.
Int J Cell Cloning. 1989 Sep;7(5):303-13. doi: 10.1002/stem.5530070607.
The capillary clonogenic cell assay was developed and adapted to culture myeloid and erythroid colonies from human bone marrow cells. The plating efficiencies for femoral bone marrow granulocyte-macrophage progenitors (CFU-gm), erythroid colony-forming units (CFU-e) and erythroid burst-forming units (BFU-e) were 0.143%, 0.229% and 0.141%, respectively. Standard bone marrow progenitor Petri dish assays require a total culture volume of 1 ml per dish, and as such are not suitable for the small numbers of cells often obtained from human bone marrow samples. The microcapillary assay as developed and standardized in our laboratory has the unique advantage of being able to utilize small numbers of cells. This technique is suitable for evaluating the myelotoxicity of investigational new anti-cancer and anti-HIV agents and for further investigation of the mechanisms underlying chemotherapy-induced bone marrow toxicity.
毛细管克隆形成细胞测定法得以开发并适用于培养来自人骨髓细胞的髓系和红系集落。股骨骨髓粒细胞-巨噬细胞祖细胞（CFU-gm）、红系集落形成单位（CFU-e）和红系爆式集落形成单位（BFU-e）的接种效率分别为0.143%、0.229%和0.141%。标准的骨髓祖细胞培养皿测定法每个培养皿所需的总培养体积为1毫升，因此不适合用于通常从人骨髓样本中获取的少量细胞。我们实验室开发并标准化的微毛细管测定法具有能够利用少量细胞的独特优势。该技术适用于评估新型抗癌和抗HIV药物的骨髓毒性，并进一步研究化疗诱导的骨髓毒性的潜在机制。
